Ishares Msci Brazil ETF vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $42.09 (market cap $13.28B), while Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B). The key difference: Ishares Msci Brazil ETF is the larger of the two by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| EWZ | IONS | |
|---|---|---|
Market Cap | $13.28B | $7.10B |
Volume | 59,308,012 | 2,027,457 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $86.50 |
52-Week Low | $29.24 | $42.38 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $6.66B |
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% on the day. The technical outlook is mixed, with moving averages signaling a bullish trend but oscillators like the RSI indicating overbought conditions. Recent news highlights significant investor focus on Brazil's upcoming presidential election, driving unusual options activity and positioning the fund as a diversifier away from U.S. tech-heavy markets.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome, which could spur volatility. Key risks include U.S.-Brazil trade tensions and domestic policy shifts, while the potential for continued commodity strength and rate cuts offers upside. Investors should weigh geopolitical factors against diversification benefits.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →